Idiopathic urticaria

This study tests a drug called remibrutinib in teenagers aged 12 to 17 who have chronic spontaneous urticaria (hives that come and go for no clear reason) that isn't controlled by antihistamines. About 100 participants will receive either the drug or a placebo for 24 weeks, with …

This study tests a new drug called remibrutinib (a tablet) against a placebo in 44 adults with chronic hives (either spontaneous or triggered by things like pressure or cold). The goal is to see if it reduces symptoms like itching and burning, and how it works in the body. Partic…

This study tracks 350 people with chronic spontaneous urticaria (hives) who are starting remibrutinib, a new drug. Researchers will survey patients and their doctors to see how well the drug controls symptoms and how satisfied patients are. The goal is to understand real-world ef…

This study tests an experimental pill called ICP-332 in 344 adults with moderate to severe chronic spontaneous urticaria (hives) that antihistamines can't control. Participants will take the drug or a placebo for 12 or 24 weeks. The main goal is to see if the drug reduces itching…

This study follows about 3,280 adults with chronic spontaneous urticaria (CSU) to see how well remibrutinib controls their hives in everyday medical practice. Participants either continue standard antihistamines or switch to remibrutinib, and researchers track symptom control and…

This study tests a new drug called lesigercept in 150 adults with chronic spontaneous urticaria (hives lasting 6+ months) that aren't controlled by standard antihistamines. Participants receive either lesigercept or a placebo injection. The main goal is to see if lesigercept redu…

This Phase 2 trial tests an injectable biologic called CM512 in 48 adults with chronic spontaneous urticaria (CSU) — long-lasting hives and itching that don't get better with standard antihistamines. Participants are randomly assigned to receive either CM512 or a placebo shot, an…

This study is observing 225 adults with severe allergic asthma or chronic hives who are already doing well on the original omalizumab drug. Their doctors have decided to switch them to a biosimilar version called Omlyclo. The main goal is to see if they stay well-controlled for 1…

This study tests an experimental drug called BLU-808 for people with chronic hives (urticaria) that don't get better with standard antihistamines. The drug works by blocking a protein called KIT, which may help control the allergic reaction causing the hives. About 105 adults wil…

This study follows about 500 adults with chronic spontaneous urticaria (CSU) who are either starting remibrutinib or sticking with standard antihistamines. Researchers will track how well the drug controls hives and itching over 24 months, and monitor for side effects. The goal i…

This program provides remibrutinib, an experimental drug, to adults with chronic spontaneous urticaria (long-term hives) that haven't improved with antihistamines or omalizumab. Participants take the drug as prescribed to help control their symptoms. The goal is to offer access t…

This study looks at whether people with chronic spontaneous urticaria (long-term hives) who are well-controlled on omalizumab every 4 weeks can switch to every 6 weeks without losing control. Forty adults will be randomly assigned to continue standard dosing or extend their injec…

This early-stage study tests a new imaging agent called 18F-4FN for PET scans to safely detect inflammation in the body. It involves 55 adults with cancer who are on immunotherapy or have suspected inflammation. The goal is to see if this agent can highlight areas of inflammation…

This study is testing a software tool called Belle.ai that uses artificial intelligence to help doctors diagnose common skin diseases. About 400 patients at dermatology clinics will have three photos taken of their skin condition. The AI will analyze the photos and suggest possib…

This study tests an experimental daily pill, ritlecitinib, for adults with chronic spontaneous urticaria (long-term itchy hives and swelling) that antihistamines don't fully control. About 200 participants will receive either 50 mg, 100 mg, or a placebo for 12 weeks, then all wil…

This study tests a new daily pill (remibrutinib) against a standard injected drug (dupilumab) for adults with chronic hives that antihistamines can't control. About 400 participants will take either the pill or get the shot for 4 weeks to see which works faster. The goal is to re…

This study compares the standard dose of cetirizine (10 mg daily) to a higher dose (40 mg daily) for treating acute hives in adults. Researchers want to see if the higher dose relieves symptoms faster and reduces the need for steroid rescue medication. Participants take the assig…

This study tests a group counseling program called Healing HEARTS to help people with conditions like obesity, skin disease, cancer, HIV, diabetes, or chronic pain deal with internalized stigma. Participants will either join the counseling program or a peer support group. The goa…

This study tests a new medication called ARS-2 for people with chronic spontaneous urticaria (long-term hives). It aims to see if ARS-2 can quickly reduce itching and hives during flare-ups. The trial involves 42 adults who will receive either ARS-2 or a placebo during separate f…

This study collects biological samples—like blood, skin biopsies, and swabs—from people with or at risk for skin diseases, as well as healthy volunteers. Researchers will use these samples to study the causes of skin conditions and explore potential treatments. Up to 700 particip…

This early-stage trial tests the safety of an experimental oral drug called EDP-978 in 98 healthy adults. Researchers will give single and multiple doses to see how the body handles it and whether it causes side effects. The drug is being developed for chronic hives, but this stu…

This study watches 400 people with chronic spontaneous urticaria (long-lasting hives) who are prescribed dupilumab by their doctor. Researchers collect information from medical records and patient surveys to see how the drug works in real life, its safety, and how it affects qual…

This pilot study is measuring prednisolone levels in 120 people with inflammatory diseases like thyroid eye disease, vasculitis, COPD, asthma, and others. Participants take high-dose prednisolone as part of their routine care, and researchers take timed blood samples to see how t…

This study looks at 320 adults who are about to start strong immune-suppressing therapy and have already had at least two COVID-19 shots. Researchers want to find out if giving a COVID-19 booster right before starting therapy or waiting six months provides better protection. Part…

This study aims to find biological markers (biomarkers) that can help diagnose and monitor chronic induced urticaria (CIndU), a condition where specific triggers like cold or pressure cause itchy hives or swelling. Researchers will compare 40 participants—including people with CI…

This study looks at different forms of IgE (a protein involved in allergic reactions) in healthy volunteers and people with conditions like severe allergies, chronic hives, mastocytosis, and immune deficiencies. Researchers aim to understand how these IgE variations relate to hea…

This study looks at how skin conditions related to cancer or cancer treatments affect the well-being of cancer patients and survivors. About 1,025 participants will fill out questionnaires about their skin condition. The goal is to better understand these effects and improve trea…